Melanoma

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Claire F Friedman, Christine Spencer, Christopher R Cabanski, Katherine S Panageas, Daniel K Wells, Antoni Ribas, Hussein Tawbi, Katy Tsai, Michael Postow, Alexander Shoushtari, Paul Chapman, Joyson Karakunnel, Samantha Bucktrout, Pier Gherardini, Travis J Hollmann, Richard O Chen, Margaret Callahan, Theresa LaVallee, Ramy Ibrahim, Jedd Wolchok

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003853; DOI: 10.1136/jitc-2021-003853
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary
Ahmad A Tarhini, Sandra J Lee, Aik-Choon Tan, Issam M El Naqa, F Stephen Hodi, Lisa H Butterfield, William A LaFramboise, Walter J Storkus, Arivarasan D Karunamurthy, Jose R Conejo-Garcia, Patrick Hwu, Howard Streicher, Vernon K Sondak, John M Kirkwood

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e004310; DOI: 10.1136/jitc-2021-004310
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al
Jeffrey Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e004347; DOI: 10.1136/jitc-2021-004347
Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
Alexander Eggermont, Michal Kicinski, Stefan Suciu

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e004272; DOI: 10.1136/jitc-2021-004272
Short-course neoadjuvant in situ vaccination for murine melanoma
Taylor J Aiken, David Komjathy, Matthew Rodriguez, Ashley Stuckwisch, Arika Feils, Vladimir Subbotin, Jen Birstler, Stephen D Gillies, Alexander L Rakhmilevich, Amy K Erbe, Paul M Sondel

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003586; DOI: 10.1136/jitc-2021-003586
B cells imprint adoptively transferred CD8⁺ T cells with enhanced tumor immunity
Aubrey S Smith, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Amalia M Rivera-Reyes, Connor J Dwyer, Michael B Ware, Anna C Cole, David M Neskey, Mark P Rubinstein, Bei Liu, Jessica E Thaxton, Eric Bartee, Chrystal M Paulos

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003078; DOI: 10.1136/jitc-2021-003078
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function
Huaishan Wang, Hui Chen, Shujing Liu, Jie Zhang, Hezhe Lu, Rajasekharan Somasundaram, Robin Choi, Gao Zhang, Lingling Ou, John Scholler, Shifu Tian, Liyun Dong, Guo Yeye, Lili Huang, Thomas Connelly, Ling Li, Alexander Huang, Tara C Mitchell, Yi Fan, Carl H June, Gordon B Mills, Wei Guo, Meenhard Herlyn, Xiaowei Xu

Journal for ImmunoTherapy of Cancer Dec 2021, 9 (12) e003339; DOI: 10.1136/jitc-2021-003339
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Jonas Bochem, Henning Zelba, Janine Spreuer, Teresa Amaral, Andrea Gaissler, Oltin T Pop, Karolin Thiel, Can Yurttas, Daniel Soffel, Stephan Forchhammer, Tobias Sinnberg, Heike Niessner, Friedegund Meier, Patrick Terheyden, Alfred Königsrainer, Claus Garbe, Lukas Flatz, Graham Pawelec, Thomas K Eigentler, Markus W Löffler, Benjamin Weide, Kilian Wistuba-Hamprecht

Journal for ImmunoTherapy of Cancer Dec 2021, 9 (12) e003439; DOI: 10.1136/jitc-2021-003439
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, Ahmad A Tarhini, James Larkin, F Stephen Hodi, Jedd Wolchok, Michael A Postow, Brian Stwalley, Andriy Moshyk, Corey Ritchings, Sandra Re, Wim van Dijck, David F McDermott, Michael B Atkins

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003743; DOI: 10.1136/jitc-2021-003743
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Toshihide Ueno, Joji Nagasaki, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yasuhiro Nakamura, Tomonori Kawasaki, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Yuzuru Ikehara, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa, Hiroyuki Matsue, Yosuke Togashi

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003134; DOI: 10.1136/jitc-2021-003134

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages